ライフサイエンスコーパス: combination vaccine

1 e response to that elicited by the IpaB/IpaD combination vaccine.

2 o be the highest dose level of 3.0 mg of the combination vaccine.

3 ween monovalent RSV cpts-248/404 vaccine and combination vaccine.

4 sponsiveness of the env DNA component in the combination vaccine.

5 strains in humans could be rectified by this combination vaccine.

6 Vaccination with the combination vaccine also led to enhanced E6-specific CD8

7 Combination vaccines and simultaneous administration of

8 s received a separate consistency lot of the combination vaccine, and 1 group received separate but c

9 Despite reduced immunogenicity, DTaP-Hib combination vaccines appear to prime for immunologic mem

10 should stimulate interest in assessing this combination vaccine approach in humans.

11 Immunization with a combination vaccine composed of highly purified native F

12 Furthermore, the combination vaccine conferred significant protection aga

13 ating the potential for the development of a combination vaccine consisting of Invaplex and other imm

14 A combination vaccine consisting of TT adsorbed to alum an

15 Here we report the efficacy of a combination vaccine containing gC2/gD2 and UL19/UL47 for

16 In guinea pigs immunized with a combination vaccine containing HIV env and HIV gag DNA p

17 e used for the assessment of new IPVs and of combination vaccines containing an IPV component.

18 ages 2, 3, and 4 months until 2004, when new combination vaccines containing inactivated poliovirus w

19 component of acellular pertussis-containing combination vaccines (DTaP-Hib) is unclear.

20 Similarly, the EEEV replicon and V/W/E combination vaccine elicited neutralizing antibodies aga

21 acterization of a recombinant hypoallergenic combination vaccine for specific immunotherapy of HDM al

22 and Dec 31, 2012, either as individual or as combination vaccines, for all age and sex groups.

23 ce to suggest that physicians should not use combination vaccines in ELBW infants.

24 We previously showed that a combination vaccine incorporating J8-DT (conserved pepti

25 ved as the number of doses of the DTaP/PRP-T combination vaccine increased (P<.02 and P=.01, respecti

26 ears of life has increased, and although new combination vaccines may eventually simplify the schedul

27 a collected from rabbits vaccinated with the combination vaccine neutralized all four targets.

28 The protection induced by a combination vaccine of AMA1 and MSP1 was not superior to

29 gella is endemic, protection studies using a combination vaccine of Shigella sonnei vaccine strain WR

30 The hepatitis A portion of the combination vaccine produced clinically acceptable high

31 Rhesus macaques were immunized with a combination vaccine regimen consisting of adenovirus typ

32 PIV3 vaccine; 16 (76%) of 21 children given combination vaccine shed PIV3-cp45 versus 11 (92%) of 12

33 se results demonstrate the potential of this combination vaccine strategy and suggest that vaccine pr

34 using the chimpanzee model to investigate a combination vaccine strategy involving sequential primin

35 The DTaP-PRP-T-HB combination vaccine studied elicits high avidity antibod

36 Incorporating combination vaccines, such as the measles-mumps-rubella-

37 nes cell envelope proteinase, we developed a combination vaccine that is highly effective in blocking

38 he UK has coincided with the distribution of combination vaccines that contain acellular pertussis (D

39 B vaccine (Engerix-B), and hepatitis A and B combination vaccine (Twinrix) were studied using the VAE

40 Treatment with the combination vaccine was also shown to enhance the antitu

41 The combination vaccine was generally well tolerated.

42 e level of protection afforded by WRSd1 in a combination vaccine was lower than the protection elicit

43 Mice receiving the combination vaccine were strongly protected against pyod

44 CONCLUSION The combination vaccines were safe and effective in elicitin

45 similar across immunization types, including combination vaccines when compared with single-dose vacc

46 or receptor (HER2) extracellular domain in a combination vaccine with a promiscuous T-cell epitope (i